3Helix, Inc. — SEC Form D Filing
3Helix, Inc. filed an SEC Form D on September 18, 2026, reporting $7.84M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- September 18, 2026
- Amount reported
- $7.84M
- Industry
- Biotechnology
- Website
- https://www.3helix.com/pages/welcome
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Collagen damage is a hidden driver of disease, disrupting normal cell communication, tissue structure, and repair processes, which leads to inflammation, tissue breakdown, and poor health outcomes.
Solution
3Helix develops bioACTIVE Collagen Hybridizing Peptides (CHPs) that selectively target damaged and remodeling collagen, promoting a localized, anti-inflammatory response to address the underlying cause of tissue damage.
Verdict
Investors backed a specialized biotech platform targeting a fundamental biological process rather than a specific disease indication. This cleared because the underlying science promised broad applicability across multiple therapeutic areas, not because the company had proven clinical efficacy in a single market. They were implicitly betting on the modularity and precise targeting capabilities of the Collagen Hybridizing Peptides (CHPs) to unlock diverse and high-value applications. What limited upside was the inherent long development cycles and capital intensity associated with translating novel peptide technologies into approved therapeutic products, requiring sustained funding beyond this initial raise.
Source: SEC EDGAR Form D filing